Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights Feb 26, 2026 04:01PM
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference Feb 17, 2026 04:01PM
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results Feb 12, 2026 04:01PM
Personalis gains Medicare coverage for lung cancer test Feb 10, 2026 06:00AM
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance Feb 10, 2026 06:00AM
View Older Stories

Feb 2, 2026 06:01AM Personalis study shows ctDNA test detects immunotherapy response early
Feb 2, 2026 06:00AM Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
Jan 28, 2026 04:01PM Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Jan 12, 2026 04:00PM Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
Jan 8, 2026 08:00AM Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
Dec 17, 2025 06:00AM Personalis study shows blood test predicts cancer patient outcomes
Dec 17, 2025 06:00AM Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
Dec 11, 2025 09:00AM New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
Nov 18, 2025 04:01PM Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nov 10, 2025 09:00AM Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
Nov 4, 2025 04:01PM Personalis Reports Third Quarter 2025 Financial Results
Oct 21, 2025 04:01PM Personalis to Announce Third Quarter 2025 Financial Results
Oct 16, 2025 09:00AM Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
Sep 15, 2025 05:35PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 10, 2025 04:05PM CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
Sep 3, 2025 04:06PM Personalis lung cancer test shows higher sensitivity in clinical trial
Sep 3, 2025 04:05PM Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
Aug 27, 2025 04:01PM Personalis to Participate in Upcoming Investor Conferences
Aug 5, 2025 04:01PM Personalis Reports Second Quarter 2025 Financial Results
Jul 22, 2025 04:01PM Personalis to Announce Second Quarter 2025 Financial Results
Jul 18, 2025 04:00PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 9, 2025 04:00PM Personalis extends Tempus partnership to include colorectal cancer testing
Jul 9, 2025 04:00PM Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
Jun 3, 2025 04:02PM Personalis, Inc. (PSNL) announces presentation of results from CALLA phase 3 study at ASCO 2025
Jun 3, 2025 04:00PM Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
Jun 2, 2025 04:00PM New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
May 22, 2025 06:00AM Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection
May 14, 2025 04:01PM Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference
May 6, 2025 04:01PM Personalis Reports First Quarter 2025 Financial Results
Apr 28, 2025 05:00PM Personalis’ NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study
Apr 22, 2025 04:01PM Personalis to Announce First Quarter 2025 Financial Results
Apr 22, 2025 06:00AM Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection
Mar 26, 2025 04:01PM Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference
Mar 3, 2025 06:00AM New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
Feb 27, 2025 04:01PM Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
Feb 18, 2025 04:01PM Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
Feb 13, 2025 04:01PM Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
Jan 28, 2025 04:01PM Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Jan 13, 2025 05:00AM New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
Jan 7, 2025 04:01PM Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
Dec 19, 2024 09:00AM Personalis, Inc. (PSNL) Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
Dec 19, 2024 09:00AM Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
Dec 16, 2024 08:00AM Personalis and Tempus Expand Collaboration to Biopharma
Nov 20, 2024 04:01PM Personalis to Participate at Upcoming Investor Conferences
Nov 6, 2024 04:01PM Personalis Reports Third Quarter 2024 Financial Results
Nov 5, 2024 04:01PM Personalis to Present at the Stifel 2024 Healthcare Conference
Oct 23, 2024 04:01PM Personalis to Announce Third Quarter 2024 Financial Results
Sep 16, 2024 09:00AM ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
Aug 22, 2024 04:01PM Personalis to Participate at Upcoming Investor Conferences
Aug 19, 2024 04:05PM Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
View Older Stories